UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $23 to $31.
UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $23 to $31.